WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) announced the completion of patient enrollment in a multi-center phase 2 clinical trial to evaluate the safety of fostamatinib, the company's oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients. Treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60.
Fostamatinib is marketed in the U.S. as TAVALISSE tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia.
Rigel expects to report topline data from the clinical trial in April 2021.
Copyright RTT News/dpa-AFX
RIGEL PHARMACEUTICALS-Aktie komplett kostenlos handeln - auf Smartbroker.de